Josh Riggs - Dec 2, 2022 Form 3 Insider Report for Oncocyte Corp (OCX)

Role
Interim CEO
Signature
/s/ Josh Riggs
Stock symbol
OCX
Transactions as of
Dec 2, 2022
Transactions value $
$0
Form type
3
Date filed
12/9/2022, 07:19 PM
Next filing
Jan 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding OCX Common Stock, no par value 2.31K Dec 2, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding OCX Option to Purchase Common Stock Dec 2, 2022 Common Stock 125K $1.33 Direct F2
holding OCX Option to Purchase Common Stock Dec 2, 2022 Common Stock 50K $5.34 Direct F2
holding OCX Option to Purchase Common Stock Dec 2, 2022 Common Stock 30K $1.39 Direct F2
holding OCX Option to Purchase Common Stock Dec 2, 2022 Common Stock 10K $1.17 Direct F2
holding OCX Option to Purchase Common Stock Dec 2, 2022 Common Stock 250K $0.46 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Restricted Stock Units vested on May 22, 2021.
F2 25% of the options will become exercisable after one year of Reporting Person's continuous employment with Issuer from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to Reporting Person's continued employment with Issuer on the applicable vesting dates.
F3 100% of the options will become exercisable after one year of Reporting Person's continuous employment with Issuer from the effective date of grant.